Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kayvirus DSM 33473 is a specific strain of a bacteriophage from the Kayvirus genus, which are lytic viruses that specifically infect and destroy Staphylococcus aureus bacteria. [8, 10, 12] It was deposited by the Czech company MB PHARMA s.r.o. in the DSMZ culture collection, the German Collection of Microorganisms and Cell Cultures. [6, 11] Kayvirus DSM 33473 is a component of DUOFAG, a two-phage cocktail also containing Pbunavirus DSM 33593, which is being developed by MB PHARMA for the topical treatment of complicated wound infections caused by S. aureus and Pseudomonas aeruginosa. [2, 4, 6, 11] Bacteriophages in the Kayvirus genus are strictly lytic, have a broad host range against S. aureus strains, and are considered promising therapeutic agents. [13, 17]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kayvirus DSM 33473.